Lytix Biopharma ASA · OSL:LYTIX
Lytix Biopharma ASA — Investordagene 2021
25 slides from Lytix Biopharma ASA's conference presentation, Oct 20, 2021
Slide 1: Lytix Biopharma AS – World leader in oncolytic molecule therapy
Lytix Biopharma AS World leader in oncolytic molecule therapy Investordagene 2021, 20. October Øystein Rekdal, CEO and Co-founder
Slide 2: Disclaimer
Disclaimer This presentation (the "Presentation") has been prepared by Lytix Biopharma AS ("Company") exclusively for information purposes. The Presentation is being made only to, and is only directed at, persons to whom such presentation may lawfully be communicated (’relevant persons’). Any person
Slide 3: First in class safety and efficacy demonstrated
FIRST IN CLASS SAFETY AND EFFICACY ENTERING PHASE II SCIENTIFIC COMMERCIAL DEMONSTRATED STUDIES IN U.S. VALIDATION VALIDATION Unique therapeutic Complete remission in LTX-315 in Phase II Confirmed by leading US Commercial deal approach animal models development and European research within skin canc
Slide 4: First in class safety and efficacy demonstrated
FIRST IN CLASS SAFETY AND EFFICACY ENTERING PHASE II SCIENTIFIC COMMERCIAL DEMONSTRATED STUDIES IN U.S. VALIDATION VALIDATION Unique therapeutic Complete remission in LTX-315 in Phase II Confirmed by leading US Commercial deal approach animal models development and European research within skin canc
Slide 5: Our unique oncolytic molecules
Our unique oncolytic molecules LTX-315 Lead product
Slide 6: Oncolytic molecules solve one of the major challenges in current cancer therapy
Oncolytic molecules solve one of the major challenges in current cancer therapy Tumors consist of many different cancer cells with different mutations
Slide 7: A new in situ vaccination principle
A new in situ vaccination principle TREATED TUMOR A cancer cell before treatment Exposure of mutations (tumor antigens) from all cancer cells LYMPH NODE Generating T cells that recognize the A cancer cell after treatment different mutations (tumor antigens) BLOOD VESSELS T cells enter the blood stre
Slide 8: First in class safety and efficacy demonstrated
FIRST IN CLASS SAFETY AND EFFICACY ENTERING PHASE II SCIENTIFIC COMMERCIAL DEMONSTRATED STUDIES IN U.S. VALIDATION VALIDATION Unique therapeutic Complete remission in LTX-315 in Phase II Confirmed by leading US Commercial deal approach animal models development and European research within skin canc
Slide 9: LTX-315 is effective in hard to treat cancer models
LTX-315 is effective in “hard to treat” cancer models B16F10 MELANOMA BRAF MUTATED MELANOMA No effect of chemotherapy or immune checkpoint inhibitors in BRAF mutated melanoma Liao, Cell Stress, 2019
Slide 10: Proof of Principle - Anti cancer effects in distant non-treated tumors confirmed in cancer patients
Proof of Principle - Anti cancer effects in distant non-treated tumors confirmed in cancer patients Two tumors treated on Local treatment generated right side T cells reduce size of other distant non-treated tumors 39 % reduction 82 % reduction Spicer, Clin. Cancer Res., 2021
Slide 11: Proof of Principle - Anti cancer effects in distant non-treated tumors confirmed in cancer patients
Proof of Principle - Anti cancer effects in distant non-treated tumors confirmed in cancer patients Spicer, Clin. Cancer Res., 2021
Slide 12: Immune checkpoint inhibitors solve a different problem in cancer therapy
Immune checkpoint inhibitors solve a different problem in cancer therapy Immune checkpoint inhibitors cure some patients Responders Failures MALIGNANT MELANOMA 60-89% TRIPLE NEGATIVE BREAST CANCER 82-95% Some cancers can protect themselves HEAD & NECK 82-87% X by activating brakes in the immune syst
Slide 13: Immune checkpoint inhibitors solve a different problem in cancer therapy
Immune checkpoint inhibitors solve a different problem in cancer therapy Immune checkpoint inhibitors cure some patients Responders Failures MALIGNANT MELANOMA 60-89% TRIPLE NEGATIVE BREAST CANCER 82-95% Immune checkpoint Some cancers can inhibitors protect themselves HEAD & NECK 82-87% can remove t
Slide 14: Combination therapy solves both problems and helps more patients
Combination therapy solves both problems and helps more patients Oncolytic molecules generate T cells that recognize different cancer cells + Immune checkpoint inhibitors keeps the brakes off and make the T cells work more efficiently
Slide 15: First in class safety and efficacy demonstrated
FIRST IN CLASS SAFETY AND EFFICACY ENTERING PHASE II SCIENTIFIC COMMERCIAL DEMONSTRATED STUDIES IN U.S. VALIDATION VALIDATION Unique therapeutic Complete remission in LTX-315 in Phase II Confirmed by leading US Commercial deal approach animal models development and European research within skin canc
Slide 16: Clinical study with LTX-315 and pembrolizumab is ongoing in US
Clinical study with LTX-315 and the immune checkpoint inhibitor pembrolizumab is ongoing in US The study is led by MD Anderson Hospital ‒ Ranks as No. 1 globally in cancer care
Slide 17: A pipeline of molecules with high commercial potential
A pipeline of molecules with high commercial potential Product Combination Population Preclinical Phase I Phase II Phase III Collaborations candidate partner ATLAS-IT-05 Patients progressed Pembrolizumab on checkpoint (Keytruda®) inhibitors LTX-315 ATLAS-IT-04 Advanced soft tissue Adoptive T-cell sa
Slide 18: Lytix targets large market opportunities
Lytix targets large market opportunities HEAD AND MALIGNANT NECK CANCER MELANOMA 130.000* 200.000* new patients diagnosed new patients diagnosed 3.7 Bn USD* 5.5 Bn USD* estimated indication value estimated indication value LIVER BREAST CANCER CANCER 260.000* 970.000* new patients diagnosed new patie
Slide 19: First in class safety and efficacy demonstrated
FIRST IN CLASS SAFETY AND EFFICACY ENTERING PHASE II SCIENTIFIC COMMERCIAL DEMONSTRATED STUDIES IN U.S. VALIDATION VALIDATION Unique therapeutic Complete remission in LTX-315 in Phase II Confirmed by leading US Commercial deal approach animal models development and European research within skin canc
Slide 20: Science behind Lytix' technology documented by world leading cancer research institutions
Science behind Lytix’ technology documented by world leading cancer research institutions Multiple collaborations leading to 50+ peer reviewed scientific publications, demonstrating the potential of oncolytic molecules
Slide 21: Nobel laureate Jim Allison is a member of our scientific advisory board
Nobel laureate Jim Allison, who discovered the first immune checkpoint inhibitor, is a member of our scientific advisory board “The ability of an activated immune response to generate a diverse T-cell repertoire that adapts to heterogeneous and genetically unstable tumors (…) make it absolutely esse
Slide 22: First in class safety and efficacy demonstrated
FIRST IN CLASS SAFETY AND EFFICACY ENTERING PHASE II SCIENTIFIC COMMERCIAL DEMONSTRATED STUDIES IN U.S. VALIDATION VALIDATION Unique therapeutic Complete remission in LTX-315 in Phase II Confirmed by leading US Commercial deal approach animal models development and European research within skin canc
Slide 23: Lytix investor - the US healthcare specialist PBM Capital
Lytix investor - the US healthcare specialist PBM Capital – invest in game changing technologies
Slide 24: Our technology already commercially validated
Our technology already commercially validated US-based biotech Regulatory milestones focused on novel based on development treatments for skin goals and sales milestones diseases at >100 mill. USD License of LTX-315 Royalty rates from the low for the treatment double-digits to the mid- of certain sk
Slide 25: Why we will succeed
Why we will succeed UNIQUE APPROACH SCIENCE VALIDATION EXECUTION Lytix’s molecules Science confirmed by Commercial deal within Management represent the missing top notch US and skin cancer Board piece European cancer Advisory Board research institutions US health specialist Competent investors Ideal